Compare Asana Inc. (ASAN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Mesoblast Limited — how do they compare? Asana Inc. trades at $8.92 (market cap $2.13B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Asana Inc. and Mesoblast Limited are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | MESO | |
|---|---|---|
Market Cap | $2.13B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $15.19 | $20.96 |
52-Week Low | $5.46 | $12.88 |
Enterprise Value | $1.96B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.23, down slightly by 0.32% today. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, revenue growth is robust with fiscal 2025 revenue reaching $723.88 million, but the company remains unprofitable with a net loss of $255.54 million. Recent news highlights AI product innovation and a strategic partnership with Norway's sovereign wealth fund, signaling positive business momentum.
The outlook for Asana is mixed. Analyst consensus leans bullish with a $10.33 price target, but persistent losses and intense competition from tech giants pose significant risks. Upside potential hinges on continued revenue growth and path to profitability, while downside risks include margin pressure and execution challenges in a competitive SaaS market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
